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Paul G Shekelle1,2*, Aneesa Motala1, Breanne Johnsen1 and Sydne J Newberry1Abstract
Background: Systematic reviews are a cornerstone of evidence-based medicine but are useful only if up-to-date.
Methods for detecting signals of when a systematic review needs updating have face validity, but no proposed
method has had an assessment of predictive validity performed.
Methods: The AHRQ Comparative Effectiveness Review program had produced 13 comparative effectiveness
reviews (CERs), a subcategory of systematic reviews, by 2009, 11 of which were assessed in 2009 using a
surveillance system to determine the degree to which individual conclusions were out of date and to assign a
priority for updating each report. Four CERs were judged to be a high priority for updating, four CERs were judged
to be medium priority for updating, and three CERs were judged to be low priority for updating. AHRQ then
commissioned full update reviews for 9 of these 11 CERs. Where possible, we matched the original conclusions
with their corresponding conclusions in the update reports, and compared the congruence between these pairs
with our original predictions about which conclusions in each CER remained valid. We then classified the
concordance of each pair as good, fair, or poor. We also made a summary determination of the priority for
updating each CER based on the actual changes in conclusions in the updated report, and compared these
determinations with the earlier assessments of priority.
Results: The 9 CERs included 149 individual conclusions, 84% with matches in the update reports. Across reports,
83% of matched conclusions had good concordance, and 99% had good or fair concordance. The one instance of
poor concordance was partially attributable to the publication of new evidence after the surveillance signal
searches had been done. Both CERs originally judged as being low priority for updating had no substantive
changes to their conclusions in the actual updated report. The agreement on overall priority for updating between
prediction and actual changes to conclusions was Kappa = 0.74.
Conclusions: These results provide some support for the validity of a surveillance system for detecting signals
indicating when a systematic review needs updating.
Keywords: Methods, Systematic reviews, UpdatingBackground
Systematic reviews are a cornerstone of evidence-based
care, either by themselves or through their incorporation
into practice guidelines, performance measures or other
evidence-based practice. To be useful, however, system-
atic reviews need to be up-to-date.
The science of determining when systematic reviews
need updating has been developing for the past decade.
Prior to 2001, no method or criterion existed to* Correspondence: shekelle@rand.org
1RAND Corporation, RAND Health, 1776 Main Street, Santa Monica, CA 90407, USA
2West Los Angeles Veterans Affairs Medical Center, 11301 Wilshire Blvd.,
Los Angeles, CA 90073, USA
© 2014 Shekelle et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.determine whether evidence-based products remained
valid or whether the evidence underlying them had been
superseded by newer work. Since then, several groups
have begun developing methods to determine signals for
updating reviews [1-5]. Most methods involve some
form of limited literature searches and the use of expert
opinion, although some methods use statistical methods
and are applicable only to meta-analytic results [6,7].
Two of these methods have been formally compared and
found to produce similar results [2]. To date, however,
no method has been assessed for predictive validity,
meaning there is no way of determining whether thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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whether the review is out-of-date. In addition to the
more easily assessed situation of a false-positive (that is,
a signal that detects that a review is out-of-date, but the
subsequent update does not result in any important
changes in the conclusions), such a study requires being
able to assess for false-negatives, which requires updating
reviews for which no signals are detected. In 2008, we
were asked to determine which of 11 systematic reviews
sponsored by the Agency for Healthcare Research and
Quality (AHRQ) Comparative Effectiveness Review (CER)
program might be in need of updating. We took advantage
of a natural experiment to assess the predictive validity of
our method for assessing for signals for updating.
Methods
In this study, we assessed the predictive validity of sig-
nals for updating CERs detected in 2009 that have since
been updated. We start with a description of the original
process used to detect signals [3] and then describe how
we assessed the validity of the signals. This original
process subsequently evolved to the process described
by Ahmadzai et al. [8]; the two are nearly identical.
The 2009 method for detecting signals
Identifying new evidence from published studies
Search strategy. We started by using the search strategy
employed in the original report. However, we limited the
search (which included at least MEDLINE/PubMed and/
or Cochrane Reviews, as well as, on a topic-specific
basis, additional databases) to five top-rated general
interest medical journals (Annals of Internal Medicine,
British Medical Journal, Journal of the American Medical
Association, The Lancet and New England Journal of
Medicine) and the specialty journals most relevant to the
topic. The specialty journals were those most highly rep-
resented among the references from the original report
(four to six specialty journals). We also modified the key
terms if, for example, we were aware of new drugs for
the condition, adding their names to the search terms.Table 1 Criteria for determining signals for updating
Label Indications for the need for an update
Still valid Original conclusion is still valid and this portion of the
we found no new evidence or only confirmatory evide
Possibly out of date Original conclusion is possibly out of date and this po
reached if we found some new evidence that might c
assessed the CER conclusion as having new evidence
Probably out of
date
Original conclusion is probably out of date and this po
reached if we found substantial new evidence that mi
assessed the CER conclusion as having new evidence
Out of date Original conclusion is out of date. This conclusion was
out of date or no longer applicable. Recognizing that
situations where a limited search would produce prim
withdrawal of a drug or surgical device from the markSearch inception dates were 6 to 12 months prior to the
end date of the original CER search in order to ensure
overlap between the searches.
Study selection and extraction. Using the same general
inclusion and exclusion criteria as the original CER, a
single reviewer experienced in systematic reviews con-
ducted a screening of the titles and abstracts and re-
quested any articles deemed relevant to the topic. From
among those articles, the reviewer extracted relevant data
from articles that met the inclusion criteria and then con-
structed an evidence table. These data included study-
level details extracted in the original CER (for example,
sample size, study design, and outcomes measured) as well
as the outcomes themselves.
Identifying new evidence from experts and expert opinion.
For each topic, we created a questionnaire matrix that listed
the key questions and conclusions from the original execu-
tive summary. The matrix was sent to experts in the field,
including the original project leader, technical expert panel
members and peer reviewers. The experts were asked to
indicate whether each conclusion listed in the matrix was,
to their knowledge, still valid and, if not, to describe any
new evidence and provide citations.
Assessing individual conclusions for signals. Once ab-
straction of the study conditions and findings for each
new included study was completed and expert opinions
were received, we assessed, on a conclusion-by-conclusion
basis, whether the new findings provided a signal for the
need for an update. Table 1 lists the criteria used for mak-
ing these determinations [9].
For each CER, we constructed a summary table that
included the following for each key question: original
conclusions, findings of the new literature search, sum-
mary of expert assessment, our final assessment of the
currency of the conclusions, and the priority for updating.
Determining priority for updating a CER. We needed
to make an overall judgment regarding the priority for
updating an entire CER. This determination rested on two
criteria. (1) How much of the CER is possibly, probably or
certainly out-of-date? (2) How out-of-date is that portionoriginal report does not need updating. This conclusion was reached if
nce and all responding experts assessed the CER conclusion as still valid.
rtion of the original report may need updating. This conclusion was
hange the CER conclusion, and/or a minority of responding experts
that might change the conclusion.
rtion of the original report may need updating. This conclusion was
ght change the CER conclusion, and/or a majority of responding experts
that might change the conclusion.
reached if we found new evidence that rendered the CER conclusion
our literature searches were limited, we reserved this category only for
a facie evidence that a conclusion was out of date, such as the
et, a black box warning from FDA, etc.
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changes to the conclusions would involve only refinement
of original estimates or whether the potential changes
would include the finding that some therapies are no
longer favored or might no longer be in use. Another
question was whether the portion of the CER that was
probably or certainly out-of-date involved an issue of
safety (for example, a drug withdrawn from the market,
a US Food and Drug Administration black box warning)
or the availability of a new drug within an existing class,
with the latter being a less important signal to update
than the former. This final determination was a global
judgment made by all the individuals working on each
particular CER. On the basis of that determination, we
classified CERs as being of low, medium or high priority
for updating. For high-priority updates, we also provided
our rationale.
Assessment of predictive validity
Our 2009 work assessed 11 CERs. We classified four as
having a high priority for updating, four as having a
medium priority for updating and three as having a low
priority for updating (see Table 2). One of the low-priority
topics, comparative effectiveness of percutaneous coronary
interventions and coronary artery bypass grafting for cor-
onary artery disease, was considered a low priority for an
update because AHRQ had already commissioned an indi-
vidual patient data meta-analysis, which it considered to
be an update of the CER and was published in 2009 [10].
AHRQ elected to support full updates of all of the
remaining CERs except the report on clinically localized
prostate cancer, for which they believed it would beTable 2 Comparative effectiveness reviews assesseda
CER
Comparative Effectiveness of Management Strategies for Gastroesophageal Reflu
Effectiveness of Noninvasive Diagnostic Tests for Breast Abnormalities [12]
Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in
Treatment [13]
Comparative Effectiveness and Safety of Analgesics for Osteoarthritis [14]
Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotic
Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriati
Comparative Effectiveness of Treatments to Prevent Fractures in Men and Wome
Osteoporosis [17]
Comparative Effectiveness of Second-Generation Antidepressants in the Pharmac
Depression [18]
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) a
Antagonists (ARBs) for Treating Essential Hypertension [19]
Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancerb [
Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary
Coronary Artery Diseasec [21]
aAHRQ, Agency for Healthcare Research and Quality; CER, comparative effectiveness
cUpdate not commissioned or individual patient data meta-analysis had already beprudent to wait for the pending PIVOT trial results [22].
This situation presented us with a natural experiment.
Because all of the reports, regardless of update priority
status, were going to get the gold standard of a complete
update, we could assess for both false-positives (reports
classified as high priority but having no major change in
conclusions when updated) and false-negatives (reports
classified as low priority that, when updated, had major
changes in conclusions) based on the 2009 predictions.
To do this experiment, we took each conclusion from the
original CER and then tried to match it with the closest
similar conclusion from the update. We then assessed the
degree of concordance between the 2009 prediction and
the updated conclusion. We used the criteria described
below.
1. Good: Concordance was considered good if the
original prediction was “still valid” and there was no
new relevant evidence or if new evidence continued
to support the conclusion, or if the original
prediction was “possibly out-of-date”, “probably
out-of-date” or “out-of-date” and new evidence
appeared that changed the conclusions by a
substantial amount.
2. Fair: Concordance was considered fair if the original
prediction was “still valid” and new evidence
supported changes in some conclusions but not
others or if the original prediction was “possibly out-
of-date” but no new evidence was incorporated into
the updated conclusions and there were no substantive
changes from the original conclusions; or if the
original prediction was “probably out-of-date” or2009 prediction Update commissioned
by AHRQ
x Disease [11] High Yes
High Yes
Patients Undergoing Cancer High Yes
High Yes
s [15] Medium Yes
c Arthritis in Adults [16] Medium Yes
n with Low Bone Density or Medium Yes
ologic Treatment of Adult Low Yes
nd Angiotensin II Receptor Low Yes
20] Medium No
Artery Bypass Grafting for Low No
review. bUpdate not commissioned pending publication of the PIVOT trial.
en commissioned.
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of the conclusions had changed but others had not.
3. Poor: Concordance was considered poor if the
original prediction was “still valid” but new evidence
substantially changed the conclusions or if the
original prediction was “probably out-of-date” or
“out-of-date” but no new evidence was incorporated
into the update and the conclusions underwent no
substantive changes.
Examples of the degree of concordance analysis are
shown in Table 3.
We assessed “concordance” rather than “agreement”
because the matching of the original conclusions to up-
dated conclusions was often challenging, and “agreement”
implies a more direct comparison of original to updated
conclusions than is always possible. For this reason, we
refrained from using a 2 × 2 table to make comparisons.
We then made a summary assessment of the CER’s
priority for updating, based on the updated conclusions.
We used the same criteria as those in the prospective
assessment: How much of the report was out-of-date
and the degree to which it was out-of-date. Using the κ
statistic, we compared the agreement between the original
assessment of priority and the actual changes.
In the assessment of concordance of individual con-
clusions, an additional complicating factor was the time
delay between our limited literature searches to assess
for signals (2008) and the search dates of the update
reports (2010 to 2012). Therefore, for conclusions with
poor concordance, we reviewed whether they may have
been influenced by new evidence published after the
surveillance signals search.
Results
We performed our assessment of predictive validity for
nine CERs comprising 149 individual conclusions. For
each CER, we present our assessment of the concordance
of individual conclusions (Additional file 1) as well as a full
table describing each conclusion and how it was assessed
(Additional file 2). We also provide an overall table that
sums up the individual conclusion assessments across all
CERs (Table 4).
The great majority (83%) of conclusions for each CER
and across CERs had good concordance. However, the
CER on gastroesophageal reflux disease (GERD) had four
“out-of-date” conclusions with only fair concordance, and
one conclusion we had assessed as “still valid” was shown
to be out-of-date.
The published 2009 updating assessment judged that
the conclusion regarding endoscopic treatment for GERD
“should be deleted”, meaning that it was out-of-date, be-
cause the endoscopic procedures had been withdrawn
from the market. However, one of the three endoscopicprocedures reviewed in the original report continued to be
used, new endoscopic procedures were introduced and
one of the two withdrawn procedures was later reintro-
duced. The update report noted this changing landscape,
and we deemed the concordance with the 2009 prediction
as only fair. A more appropriate surveillance assessment
would have been that the conclusion needed updating be-
cause the endoscopic procedures were evolving over time.
Another conclusion in the original GERD report—that
surgery and medical therapy were similarly effective—
was rated as “still valid” during the surveillance process
but had poor concordance with the update review, which
concluded that surgery was favored over medical therapy.
One of the studies providing new evidence in support of
this conclusion was published in 2009, after completion of
the surveillance signal search.
Table 5 compares our original predictions of the need
for updating with the priority as determined by the actual
update. One CER that was predicted in 2009 to be a high
priority for updating was judged to have been a medium
priority for updating based on the updated report. A CER
determined to be a medium priority update was originally
judged as having been a high priority for an update. The
updating priority remained the same for the other seven
CERs. Table 6 presents in a 3 × 3 table the results of the
overall assessment of priority for updating. The κ statistic
for agreement was 0.74 (Table 6).Discussion
This assessment of the predictive validity of a method
to assess a CER for signals for updating yielded gener-
ally favorable results. For the vast majority of individual
conclusions, concordance between the 2009 predictions
and the subsequent updated conclusions was judged to
be good. The one instance of poor concordance had new
evidence published after the surveillance signals had
been assessed, and in this instance involved a CER already
judged to be of high priority for updating based on signals
of other out-of-date conclusions.
Our present study has three primary limitations. The
first is sample size. We were able to assess only nine
CERs. However, this number included CERs assessed as
being of high, medium or low priority, thus allowing us
to assess the possibility of false-negatives (that is, CERs
assessed as low priority for updating that nevertheless
were fully updated). The likelihood of assessing such
false-negatives again is small, as it requires that low-
priority CERs be subjected to the gold standard of a full
update. Our findings that neither of the CERs judged to
be a low priority had any substantive changes in conclu-
sions will reinforce the decision to invest scarce resources
in researching other topics rather than commisioning
updates of low-priority CERs.
Table 3 Examples of degree of concordance between 2009 prediction and updated conclusiona
Examples Predictions and conclusions
Example 1
Original conclusion (from CER on
analgesics for osteoarthritis)
No clear differences between various nonaspirin, nonselective NSAIDs or partially selective NSAIDs with regard
to efficacy for pain relief or improvement
2009 surveillance assessment [14] Conclusion still valid
Conclusion from 2011 CER
update [23]
No clear difference in efficacy for pain relief, or withdrawals due to lack of efficacy
Concordance Good
Example 2
Original conclusion (from CER on
analgesics for osteoarthritis)
Etoricoxib is associated with fewer gastrointestinal adverse events than nonselective NSAIDs
2009 surveillance assessment [14] Possibly out-of-date
Conclusion from 2011 CER
update [23]
No comparable conclusion, as etoricoxib was not included because it did not gain FDA approval for sale in the
United States
Concordance Good
Example 3
Original conclusion (from CER on
second-generation antidepressants)
Overall discontinuation rates did not differ significantly between SSRIs as a class and bupropion, mirtazapine,
nefazodone, trazodone and venlafaxine. In the case of venlafaxine compared with SSRIs, higher discontinuation
rates due to adverse events appeared to be balanced by lower discontinuation rates due to lack of efficacy.
2009 surveillance assessment [16] Conclusion is possibly out-of-date, and this portion may need updating based on new analysis showing lower
dropout rate with escitalopram.
Conclusion from 2011 CER
update [24]
Meta-analyses of numerous efficacy trials indicate that overall discontinuation rates are similar. Duloxetine and
venlafaxine have a higher rate of discontinuations due to adverse events than SSRIs as a class. Venlafaxine has a
lower rate of discontinuations due to lack of efficacy than SSRIs as a class.
Concordance Fair: Escitalopram data did not end up in the conclusions
Example 4
Original conclusion from CER on
second-generation antidepressants
Three head-to-head RCTs suggest that no substantial differences exist between fluoxetine and sertraline,
fluvoxamine and sertraline, and trazodone and venlafaxine regarding relapse. Twenty-one placebo-controlled
trials support the general efficacy and effectiveness of most second-generation antidepressants for preventing
relapse or recurrence. No evidence exists for duloxetine.
2009 surveillance assessment [16] Conclusion is possibly out-of-date, and this portion of the CER may need updating to include evidence for
duloxetine.
Conclusion from 2011 CER
update [24]
On the basis of results of six efficacy trials and one naturalistic study, no significant differences exist between
escitalopram and desvenlafaxine, escitalopram and paroxetine, fluoxetine and sertraline, fluoxetine and
venlafaxine, fluvoxamine and sertraline, and trazodone and venlafaxine for preventing relapse or recurrence.
Concordance Fair: No duloxetine evidence ended up being included with regard to this key question
Example 5
Original conclusion (from CER on
management of GERD)
Medical therapy with PPIs and surgery (fundoplication) appeared to be similarly effective for improving
symptoms and decreasing esophageal acid exposure.
2009 surveillance assessment [18] Conclusion is still valid, and this portion of the CER does not need updating.
Conclusion from 2011 CER
update [25]
The 2005 CER concluded that medical therapy with PPIs and antireflux surgery were similarly effective in
improving GERD-related symptoms and decreasing esophageal acid exposure, although some surgical patients
required ongoing medical therapy postprocedure. With the addition of long-term follow-up data (7 to 12 years)
from two previously reviewed studies and results from two new RCTs, our updated review found that patients
who underwent antireflux surgery experienced a greater improvement in heartburn and regurgitation at
follow-up than did patients who received medical treatment alone.
Concordance Poor: Update indicates symptoms are better with surgery
aCER, comparative effectiveness review; FDA, US Food and Drug Administration; GERD, gastroesophageal reflux disease; NSAID, nonsteroidal anti-inflammatory
drug; PPI, proton pump inhibitor; RCT, randomized controlled trial; SSRI, selective serotonin reuptake inhibitor.
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sions to updated conclusions. In some updated reports, the
authors themselves matched the conclusions. In most cases,
however, this was not done, and, in some circumstances,determining the appropriate match to the original conclu-
sion was challenging. Additional file 2 lists each original
conclusion and its matching updated conclusion so that
readers may judge this agreement for themselves.
Table 4 Summary of concordance of predicted and actual
conclusions across nine comparative effectiveness
reviewsa
CER Good Fair Poor Total
Still valid 83 1 1 85
Possibly out-of-date 11 16 0 27
Probably out-of-date 7 0 0 7
Out-of-date 4 4 0 8
Total 105 21 1 127
aCER, comparative effectiveness review. Not applicable/no matching
conclusions/new conclusions = 22.
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2013 assessment of the 2009 predictions could not be
made in a blinded fashion. Our Evidence-based Practice
Center (EPC) did both assessments, and, even if some
other group had done the 2013 assessment, we couldTable 5 Comparison of predicted vs. actual priority for updat
CER 2009
prediction
End date o
update sea
Comparative Effectiveness of Management
Strategies for Gastroesophageal Reflux Disease [25]
High August 201
Effectiveness of Noninvasive Diagnostic Tests for
Breast Abnormalities [26]
High September
2010
Comparative Effectiveness of Epoetin and
Darbepoetin for Managing Anemia in Patients
Undergoing Cancer Treatment [27]
High April 2012
Comparative Effectiveness and Safety of Analgesics
for Osteoarthritis [23]
High January 201
Efficacy and Comparative Effectiveness of Off-Label
Use of Atypical Antipsychotics [28]
Medium May 2011
Comparative Effectiveness of Drug Therapy for
Rheumatoid Arthritis and Psoriatic Arthritis in
Adults [29]
Medium February 20
Comparative Effectiveness of Treatments to Prevent
Fractures in Men and Women with Low Bone
Density or Osteoporosis [30]
Medium March 2011
Comparative Effectiveness of Second-Generation
Antidepressants in the Pharmacologic Treatment of
Adult Depression [24]
Low January 201
Comparative Effectiveness of Angiotensin-Converting
Enzyme Inhibitors (ACEIs) and Angiotensin II
Receptor Antagonists (ARBs) for Treating Essential
Hypertension [31]
Low December
2010
aDMARD, disease-modifying antirheumatic drug; MRI, magnetic resonance imaging.not have enforced blinding, because the 2009 assessments
are in the public domain. We tried to guard against bias
by having explicit reasons for each judgment and pre-
senting these reasons for readers themselves to judge.
Our reasoning should be transparent.
With the limitation of small sample size in mind, we
offer the following preliminary conclusions about the
surveillance signal method. (1) Low-priority CERs are
unlikely to have any substantive changes in conclusions.
(2) Conclusions judged likely to be “still valid” almost
certainly are still valid. (3) Conclusions judged to be
“out-of-date” almost certainly are out-of-date. (4) Safety
concerns and the appearance of new classes of therapies
and more efficacious treatments are the best targets for
high-priority updates. (5) The classification of individual
conclusions as possibly or probably out-of-date owing to
new evidence may be slightly too sensitive as a signal; in a
number of such instances, the update report’s conclusioninga
f
rch
2013
assessment
Rationale
0 High Some procedures specifically mentioned in the
Executive Summary have been withdrawn from the
market. New procedures have been introduced.
There is a major change in the conclusion about
surgery vs. medical therapy.
Medium The new data did not change the overall conclusions
very much. The conclusion that MRI and ultrasound
may be sufficient to evaluate lesions in women at
low risk may be an important new conclusion.
High Major safety concerns leading to substantial changes
in black box warnings and practice guidelines
1 High The updated Executive Summary specifically
mentions a number of drugs that have been
withdrawn because of safety concerns.
Medium There are many new off-label indications and data
on effectiveness, but these do not indicate strong
effects of these drugs.
11 High New, expensive biologic DMARDs feature
prominently in the Executive Summary of the
updated report.
Medium There are two new drugs: zoledronic acid and
denosumab. However, there is no evidence that they
are any more effective than existing drugs. There are
signals of serious but rare new side effects, in
particular subtrochanteric fractures of the hip, but
they are not sufficient to change the initial decision
to recommend antiresorptive therapy for women
with osteoporosis.
1 Low No substantive changes in conclusions
Low No substantive changes in conclusions
Table 6 Predictive validity of priority for updating a
systematic review (2009 predicted priority)a
Priority based on actual changes in conclusions
Priority High- 2013
assessment
Medium- 2013
assessment
Low- 2013
assessment
Overall
High- 2009
prediction
3 1 0 4
Medium- 2009
prediction
1 2 0 3
Low- 2009
prediction
0 0 2 2
Total 4 3 2 9
aκ = 0.74.
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signal search was either rejected or insufficient to change
the original conclusion.
In sum, our assessment provides some support for the
predictive validity of this method of assessing CERs for
signals of the need for updating. Future research is likely
to be confined to assessing updates of systematic reviews
judged to be a medium or high priority for updating.
Further assessment of the factors leading to changes in
individual conclusions may help refine the criteria for
distinguishing between high- and medium-priority update
topics. However, investing extra time and effort to distin-
guish “possibly” from “probably” out-of-date conclusions
or to further refine the global assessment to distinguish
medium- from high-priority update topics may begin to
make the surveillance process resemble the actual update,
which is not the goal of surveillance. In this application,
the surveillance process worked very well—nearly per-
fectly, in fact (κ ≥ 0.8 is considered nearly perfect agree-
ment). No low-priority CER was judged, as having had a
substantive change to a conclusion in the update, whereas
3 of 4 high priority CERs did have substantive changes to
the conclusions. The results suggest that it is very unlikely
that new, practice-changing evidence exists concerning a
systematic review judged to be a low priority for updating
and supports a policy of delaying an update of a systematic
review until new evidence is sufficient to warrant assigning
it at least a medium priority.
The assessment method described herein represents
part of the basis for the surveillance method used to assess
AHRQ systematic reviews as described by Ahmadzai et al.
[8]. That program was designed to assess each AHRQ
systematic review every 6 months and to take 3 months
to complete. One important result is that no systematic
review was judged to be a high priority for updating at
the first 6-month assessment, meaning that it is probably
more cost-effective to assess systematic reviews no more
frequently than yearly. Additional work on making surveil-
lance more cost-effective is warranted.Conclusion
In our present study, we found evidence supporting the
predictive validity of a method for assessing AHRQ sys-
tematic reviews regarding their need for updating. One
advantage of this method relative to other proposed
methods is that it is equally useful for meta-analytic
reviews and narrative reviews. It may be applicable to
systematic reviews produced by other organizations.
Additional files
Additional file 1: Concordance of predicted and actual conclusions
for update of the nine Comparative Effectiveness Reviews. The table
presents the authors assessment of the concordance of individual
conclusions for each of the nine comparative effectiveness reviews by
listing the amount of conclusions from the report that that were “still
valid”, “possibly out of date”, “probably out of date”, “out of date”, or were
“not applicable/no matching conclusions/new conclusions” to those that
were rated as “good”, “fair”, “poor”, or “not rated”.
Additional file 2: Conclusion assessments across all nine
Comparative Effectiveness Reviews. The table presents the nine
Comparative Effectiveness Reviews conclusions for the original review,
the update review, the 2009 prediction, and the concordance for each of
the conclusions.
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